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Alzheimer disease (AD) is the most common cause of dementia in people over 60 years
old. The molecular and cellular alterations that trigger this disease are still diffuse, one
of the reasons for the delay in finding an effective treatment. In the search for new
targets to search for novel therapeutic avenues, clinical studies in patients who used anti-
inflammatory drugs indicating a lower incidence of AD have been of value to support
the neuroinflammatory hypothesis of the neurodegenerative processes and the role of
innate immunity in this disease. Neuroinflammation appears to occur as a consequence
of a series of damage signals, including trauma, infection, oxidative agents, redox iron,
oligomers of τ and β-amyloid, etc. In this context, our theory of Neuroimmunomodulation
focus on the link between neuronal damage and brain inflammatory process, mediated
by the progressive activation of astrocytes and microglial cells with the consequent
overproduction of proinflammatory agents. Here, we discuss about the role of microglial
and astrocytic cells, the principal agents in neuroinflammation process, in the development
of neurodegenerative diseases such as AD. In this context, we also evaluated the potential
relevance of natural anti-inflammatory components, which include curcumin and the novel
Andean Compound, as agents for AD prevention and as a coadjuvant for AD treatments.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common type of dementia
and usually affects people over 65. AD is characterized by accumu-
lation of intra and extracellular protein aggregates. Extracellular
deposits correspond to amyloid plaques, mainly composed of a
39 to 42 amino acids peptide called β-amyloid (Aβ), generated
by proteolytic cleavage of amyloid precursor protein (APP) by
beta and gamma secretases. Intracellular protein deposits are
named to as neurofibrillary tangles (NFTs) and are composed
of hyperphosphorylated τ protein assembled in oligomeric struc-
tures called paired helical filaments (PHF). PHF and NFT depo-
sition causes loss of synaptic function and finally neuronal death
(Giannakopoulos et al., 2003). This process of neurodegeneration
self amplifies when τ aggregates are released into the extracellu-
lar environment, since there is an important body of evidence
supporting neurotoxicity of τ aggregates (Neumann et al., 2011).
Among that evidence we can mention cell culture studies showing
that overexpression of τ alters cell morphology, delays cell growth,
and changes the distribution of organelles that are transported
through the axis by motor axonal microtubule-associated proteins
(reviewed in Cambiazo et al., 1995). Moreover, in transgenic mice
overexpressing a human τ isoform with four repeated sequences,
axonal degeneration develops in the brain and dorsal root ganglia,
and is related to accumulation of neurofilaments (Spittaels et al.,
1999).
Numerous therapeutic targets to eradicate the AD or lessen
its symptoms have been used through years of research. Among
the most studied mechanisms for AD treatment is beta amy-
loid clearance by passive or active immunization but this
methodology has been unsuccessful and even deleterious so
far (Citron, 2010). On the other hand, neuroinflammation
in central nervous system (CNS) appears as a central event
in AD pathophysiology. There are promising targets for AD
treatment in relation to neuroinflammation and the mecha-
nisms of cross talks between microglia and neurons (Fernández
et al., 2008; Morales et al., 2010; Maccioni, 2011; Neumann
et al., 2011). In this review, we will address on how neuroin-
flammatory processes are directly related to cognitive decline
and neurodegenerative processes. Moreover, we will describe
the implications of the involvement of both astrocytes and
microglia in both the inflammatory and neuroimmunomodula-
tory processes.
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NEUROINFLAMMATION
The inflammatory response is almost always a secondary response
caused by an initial event after another, like the response to
trauma or infections. However, this means it is a central mech-
anism in the neurodegenerative processes. It is this secondary
response that will ensue and probably cause a greater loss of
neurons over time as compared to the initial injury (Akiyama
et al., 2000). Inflammation plays a key role as a driving force that
can modulate the development of various neuropathologies.
Currently the term “neuroinflammation” is used to describe
the inflammatory response originated in the CNS after suffer-
ing an injury, where there is an accumulation of glial cells.
Particularly astrocytes and microglia responses converge imme-
diately after the injury occurs. In this process, cellular and
molecular immune components such as cytokines, complement
and pattern-recognition are contributing players, and they can
lead to the activation of the glial cells, i.e., microglia and
astrocytes.
Innate immunity is the first line of defense of the organ-
ism against different pathogens. Among the components of the
response we can mention pattern-recognition receptors (PRRs),
such as toll-like receptors (TLRs), nucleotide-binding, Scav-
enger receptors (SRs), among others. These receptors recog-
nize not only exogenous pathogen-associated molecular pattern
(PAMP) but also endogenous modified molecules called damage-
associated molecular pattern (DAMP). Throughout the body, the
innate immune system launches inflammatory and regulatory
responses via PRRs, phagocytes (macrophages), complement sys-
tem, cytokines, and chemokines in order to counteract infection,
injury, and maintain tissue homeostasis. Agents involved in innate
immunity, are directly related to agents involved in the develop-
ment of neuroinflammation. Cells of the CNS such as neurons,
astrocytes, and microglia along with pattern recognition recep-
tors, cytokines, chemokines, complement, peripheral immune
cells, and signal pathways constitute the basis for neuroinflam-
mation (Shastri et al., 2013).
An acute inflammatory response in the CNS is caused by
the immediate and early activation of the glial cell in response
to noxious stimuli, which is basically a defensive response that
leads to repair of the damaged area. But, if the “stimulus”
remains persistent in time, an inflammatory condition develops,
causing a phenomenon of cumulative damage over time due
to the chronic inflammatory reaction (Streit et al., 2004). All
these events precede and cause neuronal degeneration, generat-
ing complex interactions and feedback loops between glial and
neuronal cells, leading to cell damage and to the development
of a neurodegenerative disease. Thus, neuroinflammation has
beneficial or deleterious results in the brain mainly depending on
the duration of the inflammatory response (Figure 1).
It has been possible to associate a number of neu-
rodegenerative disorders of the CNS to neuroinflammatory
events, for example, based on the appearance of high levels
of several pro-inflammatory cytokines: AD, Parkinson’s dis-
ease (Ferrari et al., 2006), Huntington’s disease (Hsiao et al.,
2013), multiple sclerosis (MS), amyotrophic lateral sclerosis
(ALS; Kassa et al., 2009) among others. In all these dis-
eases neuropathological and neuroradiological studies have been
FIGURE 1 | The neuroinflammatory process. By sensing signals of
damage or injury, astrocytes and microglia suffer a gradual activation
process, leading to morphological changes and secretion of
pro-inflammatory elements (i.e., cytokines, cytotoxic elements, ROS). Thus,
the constant exposure of astrocytes and microglia to factor causing injuries
and secretion of these elements induce mutual activation of microglial cells
and astrocytes, along with neuroinflammatory process that eventually
trigger neuronal death.
performed providing evidence that neuroinflammatory responses
could start prior to a loss of neuronal cells. In this regard,
increasing evidence has been obtained on the role of cer-
tain cytokines in the direct activation of the cellular cascade
leading to neurodegeneration and AD (Table 1). It would
be interesting to identify as correlate the neuroinflamma-
tion levels that leading to release of these cytokines, which
have neurotoxic effects and are involved in the progression of
this disorder pathophysiological process (Frank-Cannon et al.,
2009).
Specifically in AD, it has been demonstrated that there is a
high expression of inflammatory mediators in the vicinity of Aβ
peptide deposits and neurofibrillary tangles, which in turn are
associated with areas of high neurodegeneration (Akiyama et al.,
2000); exemplifying the relationship between neuroinflammation
and neurodegeneration (Figure 1).
Moreover, epidemiological studies have established a link
between chronic use of non-steroidal anti-inflammatories
(NSAIDs) and reduced risk of AD (Vlad et al., 2008). These
studies reported that the use of long-term NSAID has a protective
effect against the development of the disease, delaying the onset
of the symptoms or reducing the risk of its occurrence. Although
the mechanism behind this phenomenon is still unknown, some
hypotheses are inclined to the effects of these anti-inflammatory
on the regulation of COX-1 and COX-2 protein, whose levels are
elevated in individuals with AD (Vlad et al., 2008). It has also
been observed that the regulation and blockade of the COX-1 in
microglia, by effect of NSAIDs induced an improvement in the
symptomatology of AD (McGeer and McGeer, 2007). Results in
transgenic animal models of AD, show that NSAIDs reduce in a
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Table 1 | Pro-inflammatory elements secreted by astrocytes and
microglia during the process of neuroinflammation.
Pro-Inflammatory Effect
elements
Chemokines Dysfunction, apoptosis and necrosis of neuron,
microglia and astrocytes
IL-1β, IL-6, IL-12 Astrocytes and microglia activation,
INF-γ, TNFα dysfunction, apoptosis and necrosis of neuron,
microglia and astrocytes
NO, ROS, O−2 Oxidative stress in cells; dysfunction, apoptosis
and necrosis of neuron, microglia and astrocytes
dose-dependent manner behavioral deficits and the population of
activated microglia (McGeer and McGeer, 2007).
Comparative analyses performed in the brains of cognitively
normal patients chronically using NSAIDs over age versus those
not using NSAIDs revealed no changes in the appearance of senile
plaques, but there was a 3-fold decrease in the number of activated
microglia in the brains of chronic users of NSAIDs (McGeer
and McGeer, 2007). AD patients who used NSAIDs compared
with another group of patients who did not use NSAIDs, showed
a significantly slower progression of disease (Rich et al., 1995).
These findings suggest that the protection provided by the chronic
use of NSAIDs in patients with AD may partly be derived from the
attenuation of microglial activation.
Lim et al. have conducted studies of cerebral amyloidosis
in transgenic mouse models, and gave evidence of ibuprofen
effect on amyloid plaque deposition (Lim et al., 2000). After 6
months of treatment with ibuprofen, amyloid plaque deposits
were reduced significantly in 10 months old Tg2576 transgenic
mice. Also there was a reduction in markers of astroglial and
microglial activation (Lim et al., 2000). Moreover, in double
transgenic animals ibuprofen reduced microglial activation and
decreased the number of amyloid deposits (Yan et al., 2003;
Heneka et al., 2005). In addition, Choi et al. demonstrated
that the treatment of 20-month-old triple transgenic AD (3 X
Tg-AD) mice with the COX-1 inhibitor SC-560, significantly
improved memory deficits and reduced amyloid deposition and
τ phosphorylation in the hippocampus (Choi et al., 2013). An
explanation is that the mice SC-560 treatment alters the phe-
notype of activated microglia, reducing the expression of pro-
inflammatory factors. Authors postulated that this changes in
microglial cells may play a role in the reduction of amyloid
charge and τ pathology and in rescuing impaired memory in
aged 3 X Tg-AD. As stated above, there is important evidence
that early treatment in transgenic animals with NSAIDs may
reduce neuroinflammation and Aβ peptide deposition in the
brain (Jantzen et al., 2002). In spite of that it cannot be over-
looked that not all results have been favorable, for example, in
transgenic mice models of AD, COX-2 selective inhibitors failed
to reduce the inflammatory reaction and showed an increase
in the appearance of Aβ42 peptide (Kukar et al., 2005). Recent
findings suggest that alterations in microglia and the production
of cytokines and chemokines may be an early feature that precedes
Aβ deposition in a mouse model of AD (Varvel et al., 2009). This
early microglial activation may well play a role in the appearance
of vulnerable neuronal populations, similarly to the situation
in AD.
On the other hand, clinical trials on the effects of NSAIDs
treatments of cognitive decline in Alzheimer’s disease patients
did not provide clear-cut results, data varied depending on the
cognitive test used. For example, results of trials with Naproxen
indicate that this NSAID attenuate cognitive decline, but accel-
erated cognitive decline in fast decliner patients. Conversely,
Celecoxib (another NSAID) appears to have similar effects, but
attenuated changes in fast decliners (Leoutsakos et al., 2012).
Thus, it is premature to make clinical recommendations, but the
findings to date, open several potential avenues of research, and
possibly the clinical trials should be replicated in one or more
large observational studies.
In this context, we can conclude that some NSAIDs are able
to reduce the inflammatory response caused by microglial and
astroglial cells, but some others are not as effective or may
even produce opposite results. This suggests that microglia have
different responses after exposure to different types of NSAIDs
according to specific mechanism of action of the molecule and
also to the source of the primary insult that induces the onset of an
inflammatory response. It is also plausible that the response may
vary during the course of a given therapy (Jantzen et al., 2002).
ASTROCYTES
Astrocytes are the most abundant glial cells of the nervous system
and constitute about 25% of the cerebral volume (Tower and
Young, 1973). They have multitude of functions: (i) inducing the
formation of neuronal synapses and influencing their develop-
ment (synaptogenesis); (ii) formation and maintenance of blood-
brain barrier; (iii) neurotransmission; (iv) metabolic regulation;
(v) ion balance maintenance, and finally (vi) as a component
of the “tripartite synapse” model of neurotransmission, in this
model of neurotransmission, synapse consists of three functional
elements: pre-and postsynaptic neurons and surrounding astro-
cytes. Then in addition to communication between neurons, there
is a bidirectional communication between neurons and astro-
cytes, implying a predominant role of glial cells in the physiology
of the nervous system (Matyash and Kettenmann, 2009; Chaboub
and Deneen, 2013). Astrocytes play a key role in the development
of the nervous system, since the growing of axons is guided to the
target by molecules derived from astrocytes, such as tenascin C
and proteoglicans (Powell and Geller, 1999).
Astrocytes are actively involved in synaptogenesis, not only
during development but also after CNS injury. In 1997, studies
conducted by Pfrieger observed that retinal ganglion cells synap-
tic activity was 100 times major in the presence of astrocytes
(Pfrieger and Barres, 1997). This increase in synaptic activity
mediated by astrocytes is precisely due to the increased num-
ber of synapses, which is seven times higher in retinal gan-
glion cells cultured with astrocytes in the absence of astrocytes
(Ullian et al., 2001). This increase in the number of synapses is
mediated by a matrix-associated protein named thrombospondin
(Christopherson et al., 2005; Risher and Eroglu, 2012), which
belong to a family of five homologous proteins, and at least four
of them are expressed in these cell types during development
and after brain damage, inducing synaptogenesis. These proteins
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induce ultrastructurally normal synapse formation, both presy-
naptic and postsynaptic (Barres, 2008).
On the other hand, the metabolic support given by astrocytes,
provides active neurons with metabolic substrates through a
glucose-lactate shuttle. Increased neuronal activity leads to an
increase in glutamate release, which in turn activates astroglial
Na+-dependent glutamate transporters, thus increasing cytosolic
Na+ concentration in astrocytes. In turn, increased Na+ stimu-
lates glycolysis and lactate synthesis. The lactate is subsequently
transported to neurons through specific transporters (Magistretti,
2009). The astrocytes are involved in the maintenance of home-
ostasis of brain neurotransmitters, being of particular importance
for homeostasis and turnover of glutamate by being the main sink
of glutamate in the brain. From the bulk of glutamate released
during synaptic transmission, several studies have shown that
only a minimum percentage of glutamate (∼20%) accumulates in
the neurons, while the largest amount of this neurotransmitter is
absorbed by perisynaptic astrocytes. This process of eliminating
extracellular glutamate by astrocytes, it is extremely critical to
prevent excitotoxicity (Verkhratsky and Kirchhoff, 2007).
Numerous records show that astroglial cells possess highly
important functions within the brain. However, pathological
modifications of astrocytes have been associated with several neu-
rodegenerative disorders. These include ALS, MS, AD, Parkinson’s
disease, Alexander’s disease, epilepsy and Rett syndrome (Okabe
et al., 2012). Pathological astrocytes observed in the brains of
patients with dementia were initially analyzed by Alois Alzheimer,
which found abundant glial cells in the neuritic plaques. Sub-
sequent studies have confirmed that this is a morphological
characteristic of reactive astrogliosis in AD that can be found both
in brain tissue of patients with AD, and transgenic animal models
(Verkhratsky et al., 2010). In studies of post mortem brain tissue
from patients with AD a generalized astrogliosis—manifested
by cell hypertrophy and an increase in the expression of Glial
fibrillary acidic protein (GFAP) in astroglial S100B protein—can
be found (Verkhratsky et al., 2010). A more detailed analysis of
astrogliosis in brains obtained from elderly patients (with and
without AD confirmed) has shown a correlation between the
degree of astrogliosis and cognitive impairment. However, a direct
relation between changes in astrocytes and increase in senile
plaques has been found (Simpson et al., 2010). Morphological
data show that reactive astrocytes associate with some Aβ plaques,
but not with all of them, while astrogliosis can also been found
in areas without Aβ deposits. This may result from the fact
that astrocytes may also respond to other pathological factors
in the ageing brain (Simpson et al., 2010). In the meantime, no
significant difference was found in the expression of GFAP in
brain tissue samples from patients with and without dementia
(Wharton et al., 2009). Furthermore, it has been shown that frag-
ments of Aβ promote marked inflammatory response in the brain,
causing the synthesis of different cytokines and proinflammatory
mediators (Lim et al., 2013). Within this inflammatory response,
astrocytes express a repertoire of receptors for inflammatory
cytokines (IL-1β and TNFα), chemokines and damage signals
(including TLR ligands) (Krasowska-Zoladek et al., 2007), while
other receptors and other mediators of inflammation, may be
induced after appropriate activation signals from other brain cells
(Meeuwsen et al., 2003). Studies conducted by van Kralingen,
found that a number of inflammatory cytokines were elevated
in the CNS following injury. In turn, in various neurological
conditions there are elevated levels of specific cytokines (in serum
or CSF), correlating with poor results in neurological evaluations.
These include TNFα and IL-1β, which have proven to affect the
function of the blood-brain barrier. A secondary inflammatory
response to IL-1β and TNFα, leads to astrocyte activation, being
the long-term effect of these cytokines detrimental to the survival
of astrocytes. This reveals a potential new target cell, which may
help explain some of the negative effects of these cytokines on
brain tissue during neuroinflammation (van Kralingen et al.,
2013).
MICROGLIAL CELL
Microglia are widely distributed throughout the brain and spinal
cord (Lawson et al., 1990). These cells can be found in brain,
spinal cord, retina and optic nerve, but mainly in the hippocam-
pus and substantia nigra (Venneti et al., 2009), and correspond to
approximately 5–20% of the total population of glial cells in the
CNS (Perry, 1998). These cells are considered as a representative
of the immune system in the CNS, since they possess the ability
to perform phagocytosis, release cytotoxic factors and behave as
antigen presenting cells (Hanisch and Kettenmann, 2007).
Microglia plays a key role in embryonic development as
they can secrete growth factors important for the formation
of the CNS, and also contribute to the maturation, regenera-
tion and neuronal plasticity. Furthermore, in their resting form
they also are involved in other functions such as neurogenesis,
neuroprotection and synaptic pruning, which has been found
to be complement dependent (Sierra et al., 2010; Vinet et al.,
2012). Moreover, these cells are also involved in a number of key
processes for the maintenance of homeostasis of brain microenvi-
ronment, showing various functions. For example, microglia act
as activated macrophages and they respond to any type of tissue
injury (Nimmerjahn et al., 2005). Thus, the suitable and appro-
priate function of microglial cells is essential for the homeostasis
of the CNS in both diseased and in normal health frame (Perry
et al., 2010).
Microglia under physiological conditions are usually found in
an inactivated state (or resting state) which is characterized by a
ramified morphology, small and low expression of macrophage
related molecules. When activated, drastic changes in morphol-
ogy of microglia occurs. Activated microglia are not defined by
a particular morphology, but are characterized by having few
branchings, and a larger cell body with ameboidal form (Hanisch
and Kettenmann, 2007).
Numerous signals represent a threat to the homeostasis of the
CNS, including structures and/or residues from bacteria, viruses
and fungi. Abnormal endogenous proteins, complement factors,
antibodies, cytokines and chemokines, among others, are also
sensed by the microglia elements and subsequently induce acti-
vation (Venneti et al., 2009). Thus, there are two main functional
aspects of microglial cells: immune defense and maintenance of
CNS homeostasis.
Activation of microglia by TLRs and NOD-like receptors
(NLRs) is considered to be “classical” form of microglial
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activation where innate immune responses include production
of proinflammatory cytokines like TNF-α, IL-1 and IL-6, and
chemokines. Classical activation also leads to adaptive immune
response by expressing major histocompatibility class II (MHCII)
molecules and interaction with T cells (Olson and Miller, 2004).
Under inflammatory conditions, there is an increase in active
immune response and microglia should moderate the potential
damage to the supporting tissues, repair and remodeling of
the CNS (Ginhoux et al., 2013). In this state the cells regulate
the expression of different surface markers, such as MHCII,
growth factors (Harms et al., 2013), PPRs, produce more pro-
inflammatory cytokines, such as IL–1β, IL-6, IL-12, interferon
gamma (INF-γ) and TNF-α (Xiao et al., 1996). Moreover, acti-
vated microglia increase their proliferation (Venneti et al., 2009),
synthesize and release cytotoxic factors such as superoxide rad-
icals (O−2 ), nitric oxide (NO) and reactive oxygen species (ROS)
(Colton and Wilcock, 2010; Ha et al., 2012). Therefore, it becomes
clear that microglials cell have an important role in innate immu-
nity and are the main source of pro-inflammatory factors in brain.
Microglial activation is a phenotypically and functionally dif-
ferent process, since depending on the type, intensity and context
of the stimulus; microglial response has a potential neuropro-
tective or pro-inflammatory effect (Hanisch and Kettenmann,
2007). It is precisely this delicate balance between the neurotoxic
and neuroprotective and between pro-inflammatory and anti-
inflammatory which determines the role of microglia in a dis-
ease or condition. So based on the current research, microglial
activation should not be considered as an all or nothing event
or single process, and we must realize that the answers to the
pathological events depends on context and adapt as changes in
the microenvironment occurs.
Studies by Nimmerjahn revealed that microglial processes
and arborizations are highly mobile (Nimmerjahn et al., 2005).
These are continuously being reconstructed by de novo for-
mation and removal of processes, similar to the movements
of the filopodia. Such a dynamic and thorough reorgani-
zation may allow microglia to fully explore their environ-
ment in any situation without disturbing the structures of
near neurons. Thus, it is estimated that the entire brain
parenchyma could be monitored in a few hours. This is pos-
sible because neighboring microglial cells take turns scanning
shared regions, ensuring comprehensive detection, avoiding their
own contact. This exploration generated by random processes
that change quickly, can lead to the translation of microglial
cells into a particular site induced for microdamage. Moreover,
microglia cells also have many receptors for a large num-
ber of molecules, which can immediately detect signs of dis-
ruption in the structural and functional integrity of nervous
tissue.
In-vitro studies have shown that microglial cells participate
in the removal of Aβ peptide in culture (Hardy and Selkoe,
2002). But there is also possible that Aβ protofibrils activate
microglia, triggering an inflammatory response and the subse-
quent release of neurotoxic cytokines. On the other hand, studies
in patients receiving NSAIDs in long term treatment revealed a
decrease in the incidence of AD, suggesting that attenuation of
the inflammatory response may help prevent or maintain a lower
FIGURE 2 | τ aggregates potentiate the neuroinflammatory process.
Activated microglia and astrocytes, induce neuronal death through
neuroinflammatory process, allowing the release of τ protein aggregates
from the dead neuron. These aggregates of τ are capable of inducing
activation of microglia and astrocytes, as well as neuronal death, thus
producing a circuit of constant neuroinflammation. Considering the possible
protective effects of curcumin, neuronal death could be delayed or inhibited
by this compound, halting this circuit of neuroinflammation. Furthermore,
the nutraceutical complex Brain Up-10 acts on τ aggregates, and may
prevent neuronal death and activation of microglia and astrocytes, stopping
the circuit and the development of neuroinflammation.
probability of developing AD (McGeer et al., 1996, 2006; Fernán-
dez et al., 2008; Town, 2010). Even in mice, NSAIDs directly affect
the development of amyloid in the brain, reducing Aβ-42 peptide
levels (Weggen et al., 2001). This highlights the important role
of pro-inflammatory cytokines released as a result of microglial
activation and the effect of the damage signs, as major players in
the development of AD (Figure 1).
In this context, authors Fernandez and Maccioni, have
hypothesized the central role of neuroimmunomodulation in the
pathogenesis of AD. In this model a number of innate damage
signals, which manifest persistently over time, are able to induce
microglial activation, triggering an overactivation state in the cells
(Fernández et al., 2008; Maccioni et al., 2009; Morales et al., 2010).
As prolonged exposure to damage signals generate overacti-
vation of microglial cells, the steady release of cytotoxic factors
and pro-inflammatory cytokines causes a neuroinflammatory
phenomenon which is directly related to neuronal degeneration,
mainly as a result of pro-inflammatory molecules (Li et al., 2007;
Colton and Wilcock, 2010; Morales et al., 2010), positioning
directly microglia and cytokines as key elements in the develop-
ment of neurodegenerative disorders such as AD (Mrak, 2009;
Figure 2).
Pathological τ aggregates are able to induce microglial activa-
tion with the subsequent events related to the neuroinflammatory
cascade. After neuronal death, pathological τ protein aggregates
are released into the extracellular medium causing activation
of microglia and generating a cascade of constant feedback of
damage signals (Morales et al., 2013).
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NEW RESEARCH AVENUES
Today, as a result of the lack of effectiveness of current treatments
for AD, a lot of effort has been invested to enhance the search
for new therapeutic targets. Based on the results obtained in
patients taking anti-inflammatory drugs, a new possibility has
been opened studying the association of inflammatory processes
and AD pathophysiology.
An important strategy to prevent brain impairment is based
on dietary changes and nutritional supplements, functional foods
and nutraceuticals. In this regard, there is interesting information
coming from studies with the antioxidant and antiinflammatory
Andean Compound (called initially as Andean Shilajit). Andean
Compound is a very complex mixture of humic substances gener-
ated by natural millenary decomposition of vegetal material and is
originated as an endemic natural product from the Andes Moun-
tains. Andean Compound and its major active principle—fulvic
acid—emerge as novel nutraceutical with potential uses against
neurodegenerative brain disorders (Carrasco-Gallardo et al.,
2012a). This natural compound is a potent anti-inflammatory
substance, and a very safe dietary supplement (Carrasco-Gallardo
et al., 2012b). In fact, according to studies by Cornejo et al. (2011),
fulvic acid is able to block τ self-aggregation affecting the length
and morphology of PHFs generated in vitro. Additionally, after
exposure of preformed τ fibrils to fulvic acid, a decrease in length
of PHFs can be detected (Cornejo et al., 2011).
Therapies based on τ protein, appear as an interesting target
because tangle formation has been identified as a major event
involved in the neurodegenerative process. Currently, our group
is working in a compound that contains Andean Compound
plus complex B vitamins (i.e., B6, B9 and B12 vitamins) named
as Brain-Up 10®, underwent a pilot clinical trial and showed
a tendency toward less cognitive deterioration, a reduction on
neuropsychological symptoms and less distress for the caregiver
of treated patients.
Another compound of natural origin, which is currently under
study, is curcumin. Curcumin is a natural phenolic compound
derived from the perennial herb Curcuma longa (turmeric), and
is well known to exhibit anti-inflammatory and antioxidant activ-
ities (Aggarwal and Harikumar, 2009; Lu et al., 2014). In India,
turmeric has traditionally been used for the treatment of diseases
associated with injury and inflammation. The information about
this compound reported that it may be capable of preventing
the death of neurons in animal models of neurodegenerative
disorders, but its possible effects on development and neuroplas-
ticity are unknown (Kim et al., 2008). Studies led by the author
Kim revealed that curcumin has a dual action in cell cultures of
NPC (multi-potent neural progenitor cells): at low concentrations
stimulates cell proliferation, whereas at high concentrations it
becomes cytotoxic. On the other hand, the administration of
curcumin to adult mice resulted in a significant increase in the
number of newly generated cells in the dentate gyrus of hip-
pocampus, indicating that this compound enhances adult hip-
pocampal neurogenesis (Kim et al., 2008). Then, curcumin would
stimulate developmental and adult hippocampal neurogenesis,
with a biological activity that may improve neural plasticity and
repair. Recent studies have shown that curcumin was able to
prevent damage from Aβ, because it induced decrease in CaMKII
Table 2 | Natural compounds recommended in the treatment AD.
Compound Active principle References
Ginkgo biloba Ginkgo extract EGb761 Canevelli et al. (2014)
Vellas et al. (2012)
Resveratrol 3,4,5-trihydroxystilbene Lu et al. (2012)
Kang et al. (2009)
Cerebrolysin Porcine brain-derived Wei et al. (2007)
peptide Rockenstein et al. (2006)
Álvarez and Fuentes (2011)
function in organotypic hippocampal slices, attenuating synap-
tic dysfunction, inducing the development of more robust and
synaptically efficient neurons, and this is reflected in the inhibi-
tion of synaptic dysfunction and neuronal death (Hoppe et al.,
2013). These results expand the neuroprotective role of curcumin
to a synaptic level, enhancing this compound as an alternative
or add-on treatment for AD (Figure 2). In both examples—i.e.,
Brain-Up 10® and curcumin—we show that by looking at natural
compounds it is possible to find new alternatives in the search
of treatments for AD, so it is important not only to continue
generating new synthetic compounds, but also to revisit old
traditional medicine as well.
Other compounds have been used for supplementary treat-
ment of AD (Table 2). Ginkgo biloba has been highly investigated
but the data are confusing. Thus, Canevelli proposes that Ginkgo
biloba may provide some cognitive benefits in AD patients, but
only in cases under cholinesterase inhibitors treatment, but the
clinical output of such effects remains to be clarified (Canevelli
et al., 2014). On the other hand, in 2012 Vellas and coworkers
conducted several clinical trials to study the effect of Ginkgo biloba
extract in AD patients and healthy elderly subject that used this
compound for longer periods of time. They aimed to assess the
efficacy of 5 years’ administration of a standardized Ginkgo biloba
extract, widely used as coadjuvant in the treatment of patients
with cognitive disorders. However, the results failed to show a
protective effect in this type of cognitive disorders (Vellas et al.,
2012).
Resveratrol is a powerful antioxidant that is present in many
plants, including grapes, peanuts and plums, that protects against
environmental stress. This compound has been extensively inves-
tigated for their potential properties in cardioprotection, anti-
inflammatory effects, anticancer, and antiaging effects. It was also
shown recently that it inhibits Aβ aggregation in vitro (Lu et al.,
2012). The problem is that it exhibits a low bioavailability in the
organism (Kang et al., 2009). On the basis of knowledge that
resveratrol possesses a variety of bioactivities, a novel series of
derivatives have been generated and tested as multi-target agents
for AD treatment (Lu et al., 2012).
Another compound used in AD treatment is Cerebrolysin.
This compound is a neuropeptide preparation consisting of low-
molecular-weight peptides and free amino acids. This compound
mimics the action of endogenous neurotrophic factors, and it is
postulated that a mixture of this peptide with neurotrophic effects
may reduce neurodegenerative pathologies (Rockenstein et al.,
2006). Wei et al. proposed that the main effects of Cerebrolysin
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include neurotrophic stimulation, neuroimmunological regula-
tion and the improvement of glucose transportation across blood-
brain barrier (Wei et al., 2007). After conducting a meta-analysis
of six clinical trials, these authors, have postulated that Cere-
brolysin could improve the clinical condition of AD patients, but
large-scale trials are needed to provide convincing evidences of
the efficacy of this compound on cognitive function and activities
of daily living in AD (Wei et al., 2007). Further experimental
research is needed to elucidate the molecular mechanism involved
in some of the pleiotropic activities of Cerebrolysin, and partic-
ularly its influence on neuroinflammation, as well as to identify
their possible interactions with neurotrophic factors and brain
receptors (Álvarez and Fuentes, 2011). Main features of these
agents are summarized in Table 2.
CONCLUSION
The development of AD involves a series of perturbations and
imbalances that systemically affect the normal functioning of
the CNS, triggering a condition of dementia. Despite scientific
advances and knowledge that exists regarding the AD, still it
has not been possible to develop effective treatment options. As
it is now, most available treatments are designed against AD
symptoms, and serve only as palliative treatments. In this context,
Neuroimmunomodulation hypothesis appears as a guide in the
search for new targets that have not been considered before, for
developing effective treatments. This is the case of τ protein,
which under pathogenic conditions self-aggregates and becomes
one of the most important actors in the neurodegenerative
cascade.
Based on the results of studies on long-term exposure to anti-
inflammatory drugs, that show that these drugs are associated
with a decreased risk of developing AD, a new interesting therapy
may be available. NSAIDs may protect people from Alzheimer
through several potential mechanisms that are associated with
the disease based on the neuroinflammatory theory (Akiyama
et al., 2000; Szekely et al., 2004). For example, they can reduce
the inflammatory processes in the brain, because these drugs can
inhibit the inflammatory response of microglial and/or astrocytes,
reducing cell death due to excitotoxicity mediated by glutamate
(Casper et al., 2000).
But the use of these type of drugs requires definitely more
exploration and analysis, especially of the mechanism of action
leading to an improvement in the patient after prolonged use.
The same applies to any neuroprotective effect, since this is a very
sensitive issue that should be considered to estimate the effect of
these drugs in the body.
The appearance of new compounds that can open the way
to new treatments becomes a necessity. In this search we can
mention compounds such as curcumin and Andean Compound,
which, because of their natural origin and the lack of adverse
effects, appears as promising preparation for AD prevention.
Studies that have been made on these compounds are very recent,
but give strong evidence that its effects are mediated by disruption
of the inflammatory response and self-aggregation of the τ pro-
tein, positioning them as a future therapeutic option for neuronal
injury.
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